IFPA Forum Americas 2025: “Towards More Equitable, Person-Centered Care for All People Living with Psoriatic Disease in the Americas”
On April 4, 2025, IFPA will host the IFPA Forum 2025 for…
Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem
TARRYTOWN, N.Y. and WASHINGTON, March 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals,…
Free online course from KnowledgeActionChange introduces new approaches in fight against smoking-related death and disease
LONDON, March 10, 2025 /PRNewswire/ -- UK-based public health agency, Knowledge•Action•Change (K•A•C), is launching…
ACTG Presents Study at CROI Demonstrating Increased Risk of Obesity and Cardiometabolic Disease After Switch to Integrase Inhibitor-Containing Regimen
LOS ANGELES, March 08, 2025 (GLOBE NEWSWIRE) -- ACTG, a global clinical…
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
March 01, 2025 12:45 ET | Source: Celldex Therapeutics, Inc. - Greatly…
NYSE CONTENT ADVISORY: PRE-MARKET UPDATE + RARE DISEASE DAY AWARENESS
NEW YORK, Feb. 28, 2025 /PRNewswire/ -- The New York Stock Exchange…
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohns disease
ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and…
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 ReinforcingBest-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohns Disease
Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET…
Egetis Therapeutics to Feature MCT8 Deficiency on Behind the Mystery Airing on Lifetime in Honor of Rare Disease Day
STOCKHOLM, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Egetis Therapeutics AB (publ) (“Egetis”…
Datar Cancer Genetics Introduces Revolutionary Tumor-Agnostic + Informed Blood Test for Residual Disease Monitoring
The Target-MRD blood test uses a combination of tumor-informed and tumor-agnostic molecular…